The intracellular roles of Granzyme B (GrB) in immune-mediated cell killing have been extensively studied. Recent data also implicate GrB in extracellular pathways of inflammation, cytokine activation and autoimmunity. Targeting (GrB) provides a new pharmaceutical agent for various inflammatory disorders. Serpina3n is a mouse extracellular inhibitor of GrB. There is no apparent equivalent in humans. In this study, we used a novel applied genetics approach to engineer a new extracellular GrB serpin. A chimeric protein was generated in which the reactive center loop (RCL) of human extracellular antichymotrypsin (ACT) was replaced with that of serpina3n. This serpin contained 27 amino acid residues from the serpina3n RCL and the remaining 395 residues from human ACT. The insertion converted human ACT into a GrB-inhibitory serpin. Several critical residues were identified by scanning mutagenesis on the chimera and serpina3n. Targeted mutagenesis was conducted on wild-type human ACT by specifically substituting those critical residues, creating a novel inhibitor that contains 99.3% human ACT sequence with only three point mutations. Wild-type human ACT had a k ass for GrB of 2.26 × 10 4 M −1 s −1 , whereas the novel inhibitor binds GrB with a k ass of 7.65 ×
Introduction
Granzyme B (GrB) plays a key role in the cell-mediated death pathway of immunity. Apoptosis is vital for maintaining multicellular organisms through controlled removal of damaged or infected cells as well as unwanted cells during development (Afonina et al., 2010) . Upon recognition of the target cell, cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells release granules containing perforin and GrB into the immunologic synapse. Perforin facilitates the entry of GrB into target cells. Once inside, the process of apoptosis begins with GrB activating a family of proteases known as caspases, by proteolytic cleavage . When activated, caspases cleave various intracellular substrates in the target cell to cause cell death (Fischer et al., 2003; Taylor et al., 2008) . GrB also induces apoptosis through the mitochondrial/apoptosome pathway Heibein et al., 2000) . GrB proteolytically cleaves BH-only (Bid) protein, which leads to Bax/Bak oligomerization at the mitochondrial membrane, pore formation and the release of cytochrome c. Aside from these two traditional pathways of GrB in apoptosis, emerging evidence shows that GrB targets downstream or separate pathways to remove unwanted cells. GrB induces DNA fragmentation by cleavage of an inhibitor of DNase, DFF45/ICAD, resulting in a release of DNase (Thomas et al., 2000; Sharif-Askari et al., 2001) . GrB can disrupt components of the cytoskeleton by targeting the c-terminus of α-tubulin, which is critical for regulating microtubule polymerization (Sackett et al., 1985; Adrain et al., 2006; Goping et al., 2006) . Thus, GrB may suppress the mitotic potential of tumour cells and limit viral replication as many viruses utilize the host microtubule network (Adrain et al., 2006) . Recently, we discovered that GrB directly targets the translational machinery by proteolytic cleavage of the eukaryotic initiation factor eIF4G3 (Marcet-Palacios et al., 2011) . This pathway prevents virus replication before the onset of apoptosis, supporting that GrB has nonapoptotic roles.
In addition, extracellular GrB has been implicated in a variety of disease states. Synovial GrB levels are elevated in subjects with chronic inflammatory conditions such as rheumatoid arthritis, with systemic GrB levels several hundred-fold higher in affected patients (Tak et al., 1994 (Tak et al., , 1999 . GrB may mediate cartilage degradation in rheumatoid arthritis (Ronday et al., 2001; Goldbach-Mansky et al., 2005) . Levels of circulating GrB are also higher in the bronchoalveolar lavage of atopic asthma patients compared with controls (Bratke et al., 2004) . Aside from the postulate that GrB leaks into the immunologic synapse during intense activation of CTLs and NK cells (Afonina et al., 2010) , other non-cytotoxic cells express GrB and could be contributing to the high circulating levels of GrB, e.g. dendritic cells, mast cells, basophils, B-lymphocytes, macrophages, keratinocytes, platelets and human articular chondrocytes (Rissoan et al., 2002; Horiuchi et al., 2003; Hernandez-Pigeon et al., 2006; Tschopp et al., 2006; Kim et al., 2007; Strik et al., 2007; Freishtat et al., 2009; Hagn et al., 2009) .
GrB may have a role in atherosclerosis as GrB expression in atherosclerotic lesions correlates with disease severity (Choy et al., 2004) , and higher levels of GrB are measured in patients with unstable plaques (Boivin et al., 2009) . T-lymphocytes are the most abundant immune cell type expressing GrB in an atherosclerotic lesion, along with CD4+/CD8+ macrophages and foam cells (Choy et al., 2003; Baba et al., 2006; Kim et al., 2007; Daugherty et al., 2008 Daugherty et al., , 2009 ). Clinically, increased GrB levels in plasma correspond to an increased incidence of cerebrovascular events and carotid plaque instability (Skjelland et al., 2007) , possibly due to GrB's activity on the extracellular matrix (ECM) (Choy et al., 2004; Buzza et al., 2005; Boivin et al., 2009) . Numerous ECM substrates of GrB are reported in the literature (Hiebert and Granville, 2012) , including vitronectin, fibronectin, laminin, decorin and the smooth muscle cell matrix (Choy et al., 2004; Buzza et al., 2005; Ang et al., 2011) . Cleavage of ECM components by GrB may contribute to disease, not only through mechanical damage, but other mechanisms such as anoikis, a form of cell death that results from loss of cell-matrix interactions (Choy et al., 2004; Buzza et al., 2005; Boivin et al., 2009) . Thus, GrB is a multifunctional protease with an important role in a variety of inflammatory diseases, making GrB a critical target for drug development (Boivin et al., 2009) .
Normally, protease activity is tightly regulated to avoid unintended damage to host cells. Serpins are proteins that inhibit proteases by forming complexes with the proteases. Human protease inhibitor-9 (PI9) or SERPINB9 is an inhibitor of GrB. High levels of PI9 can be found in dendritic cells, lymphoid endothelial cells, non-lymphoid endothelial cells, and in cells of immune-privileged tissues such as the eye, testes, ovaries and placenta (Bladergroen et al., 2001) . PI9 was originally identified in T-lymphocytes and thought to be protective against apoptosis induced by GrB (Hirst et al., 2003; Bots et al., 2006) . It is an intracellular cytosolic protein, and there is no evidence that it has activity outside the cell. GrB retains 70% of its activity in human plasma, suggesting a lack of effective inhibitors in plasma (Kurschus et al., 2004) . In support, Kurschus et al. (2004) have shown that GrB activity is not inhibited by human plasma in vitro. Sipione et al. (2006) discovered a novel murine serpin secreted by sertoli cells known as serpina3n, which can bind and inhibit the activity of GrB. Serpina3n inhibits rupture in a mouse model of aortic aneurysm (Ang et al., 2011) . As an extracellular protein, serpina3n is more plasma stable, but as a murine protein, would elicit an immune response if introduced in humans. Alpha-1 antichymotrypsin (ACT) is a human protein but unable to effectively bind GrB. Thus, our objective was to create a chimeric protein with the GrB inhibitory property and plasma stability of serpina3n and non-immunogenicity of human ACT.
Materials and methods

Materials
Cell lines Jurkat cells were obtained from American Type Culture Collection. Cells were passaged when the cell density reached 10 6 cells/ml.
RPMI was supplemented with 10% fetal bovine serum, 0.06 mg/ml penicillin and 0.01 mg/ml streptomycin sulfate.
Adenovirus-mediated internalization of GrB GrB was internalized into Jurkat cells to induce apoptosis using a nonreplicating strain of adenovirus (AD) (Froelich et al., 1996) . AD was used at 200 plaque-forming unit (PFU) per cell. Experiments where Jurkat cells were treated with GrB and contained AD was referred to as 'GrB/AD treatment'.
In vitro transcription translation TNT quick-coupled transcription/translation kit (Promega, WI, USA) was used for in vitro transcription translation (IVTT). Individual reactions were performed as previously described (Marcet-Palacios et al., 2011) and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
GrB binding
This technique was conducted with freshly made IVTT serpins or with serpins purified through fast protein liquid chromatography (FPLC). Equimolar concentrations of serpins and GrB were incubated in PBS for 30 min at 37°C. Radioactively labeled IVTT products were visualized after SDS-PAGE and autoradiography. FPLC-purified serpins were analyzed through SDS-PAGE and visualized by silver staining.
SDS-PAGE
Ten percent polyacrylamide gels were used. Electrophoresis was conducted in a mini protean 3 cell (Bio-Rad) with a Power Pac 1000 (Bio-Rad) (Marcet-Palacios et al., 2011) .
RCL chimera
ACT chimera was obtained from GenScript (GenScript Corporation, NJ, USA). The reactive center loop (RCL) of murine protein serpina3n (residues E369-P395) was used to replace the RCL of human ACT (residues E371-P398) (Fig. 1C) .
Site-directed mutagenesis
Both scanning and target mutagenesis were carried out using the Quikchange site-directed mutagenesis kit and oligonucleotide primers described in Table I . Following the PCR by Pfu Ultra High Fidelity DNA polymerase, the product was treated with DpnI, and then transformed into competent cells Escherichia coli DH5α. Using colony PCR, three to four colonies were analyzed from each reaction. Positive products were purified using a QIAquick ® PCR purification kit and subsequently sent for sequencing. Large-scale plasmid preps were made and used in IVTT reactions. 
FPLC purification
To prepare the target mutants of ACT for FPLC purification, 6× Histag was added to the N-terminus of the mature form of ACT starting with the sequence NSPLDE. The resulting PCR fragments were digested with BamHI and inserted into the BamHI site of the expression vector pET-3c, followed by sequencing of the inserted fragments. The plasmid pET-3c with each mutant was inoculated in E. coli BL21 (DE3). From the overnight culture, a 1 : 20 dilution was grown at 37°C until OD600 was 0.5. Protein expression was induced with 0.2 mM isopropyl-β-D-1-thiogalactopyranoside, and the following cultivation was continued for 4 h at 37°C in the 4 l media. Cells were pelleted at 7000 g for 20 min. The pellet was resuspended in native lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, 5% glycerol, pH 8). Lysozyme (0.2 mg/ml) and protease inhibitor phenylmethylsulfonyl fluoride (1 mM) were added to the suspended cells. Sonication was conducted with a standard probe 80% power for six pulses for 15 s each. Immobilized metal ion affinity chromatography purification was conducted. Protein was eluted with Buffer B (50 mM NaH 2 PO 4 , 300 mM NaCl, 500 mM imidazole, 5% glycerol, pH 8) with 0-100% over 30 ml at 2.5 ml/min. During elution 2.5 ml fractions were collected. All samples were evaluated by SDS-PAGE to determine which fractions contained the protein of interest. Fractions containing the desired protein were pooled together and loaded into a PD-10 column pre-equilibrated with Q 0 (20 mM TRIS pH 8, 0.1 mM EDTA, 0.5 M NaCl and 5% glycerol). Desalting was conducted by eluting with 4 ml of Q 0 . Further purification was conducted by passing the sample through a Hi-TrapQ HP column. Elution was conducted by passing Buffer B with 0-100% over 30 ml at 2.5 ml/min. During elution, 2.5 ml of the sample was collected. Sample desalting was conducted by passing the sample through a YM-10 column and eluted with Q 0 . Protein concentrations were determined and aliquots were flash frozen.
GrB enzymatic assay
GrB activity and serpin-mediated inhibition were measured by a colorimetric assay as described previously (Ewen et al., 2003) . Hydrolysis of the GrB substrate Ac-IEPD-pNA (Kaiya Biomedical, Seattle, WA) was monitored at A 405 . Human GrB was incubated for 30 min at 37°C to allow for GrB-serpin interaction.
Enzyme kinetics for human GrB inhibitors
Stoichiometry was determined as previously described (Sun et al., 1996) . The second-order rate constant was calculated as previously described (Sun et al., 1995) . Equimolar amounts (0.2 μM) of GrB and serpin molecules were combined and incubated at 37°C for 0-120 min to determine residual activity. The reaction buffer with Ac-IEPD-pNA was added and incubated at 37°C for 1 h.
Results
The RCL of serpina3n confers ACT the ability to bind to GrB
Serpina3n is an effective inhibitor of human GrB (Sipione et al., 2006) . Serpins form an SDS-stable complex with their target enzymes.
Radioactively labeled serpina3n bound purified human GrB or recombinant human GrB (rGrB) as demonstrated in an IVTT binding experiment (Fig. 1A) . In this experiment, serpina3n ran at a MW of 47 000 but when bound to GrB, this shifted to MW 78 000. Human ACT did not bind GrB in this system, despite a high sequence homology between the two genes (Fig. 1B) . To study the role of the RCL in conferring serpina3n its GrB-binding specificity, we replaced human ACT RCL with that of serpina3n (Fig. 1C) . To build this chimera, the human ACT residues E371-P398 were extracted and replaced with the serpina3n residues E369-P395. This human ACT chimera (ACT mRCL ) formed the SDS-stable complex with human GrB as demonstrated in Fig. 1B . Thus, the serpina3n RCL residues E369-P395 conferred human ACT the ability to bind GrB.
Critical serpina3n RCL residues are necessary to induce optimal binding to GrB
Serpina3n RCL spans 27 amino acids from E369-P396 (Fig. 1C) . The P1 residue within this region is Met
390
. Point mutation of this residue to alanine, in either native serpina3n (serpina3n mM381A ) or in the human ACT chimera (ACT mRCL(M383A) ), resulted in a loss of GrB binding (Fig. 1D) . Interestingly, replacement of P1 Met residue by either aspartic acid or glutamic acid generated mutants that retain GrB-binding properties (Fig. 1D ) in both the ACT chimera (ACT mRCL(M383E)/(M383D) ) and serpina3n (serpina3n mM381E/M381D
). To determine which residues within the RCL were critical in conferring serpina3n its GrB specificity, we conducted scanning mutagenesis of residues P4-P4′ in both native serpina3n and ACT mRCL .
Disappearance or reduction in the intensity of the 78 000 MW band indicated reduced binding. Replacement of residues in Positions P1 and P3′ with alanine had the most significant impact in reducing native serpina3n binding to GrB ( Fig. 2A) , while scanning mutagenesis in ACT mRCL identified residues P3 and P4′ as important, in addition to the P1 site (Fig. 2B ).
Three mutations in human ACT transform this protein into a GrB inhibitor
Following the identification of these four critical residues, we proceeded with the sequential point mutation into wild-type ACT (ACT WT ) (Fig. 2C) . Replacement of the P1 residue with methionine (ACT mP1 ) turned ACT WT into a GrB-binding protein (Fig. 2D) . We then point-mutated this construct and replaced a leucine residue at the P3′ position with a lysine (ACT mP1,P3′ ). Although P3′ appeared GCAGTCAAAATCGTCCTCATGTCTGCATTACTGGAGACAAGGACCAT ACT m P3,P1,P3′,P4′ GCAGTCAAAATCGTCCTCATGTCTGCAAAACTGGAGACAAGGACCAT Fig. 2 . Scanning mutagenesis analysis of serpina3n (ser3n) and ACT identified three critical RCL residues. IVTT in the presence of radioactively labeled methionine (MetS35) was conducted for all tested serpins. Each radioactively labeled serpin was then incubated with purified GrB in a binding assay. Samples were then separated by SDS-PAGE, and developed through autoradiography. A shift in the serpin molecular weight was interpreted as formation of serpin-GrB complex. (A) Serpina3n (ser3n) scanning mutagenesis where P4-P4' residues were sequentially mutagenized to alanine. Mutagenesis of Ser3n mA383A was not conducted since there is an alanine already present at that P2' site. We added the symbol asterisks to indicate this in the figure (Ser3n mA383A* ). (B) ACT mRCL scanning mutagenesis where P4-P4' residues were sequentially mutagenized to alanine. Scanning mutagenesis was not conducted on the ACT chimera (ACT mRCL )
containing the ser3n RCL. We added the symbol asterisk to indicate in the figure that ACT mA385A was not mutagenized as an alanine is already present in the P2' site. (C) Wild-type ACT (ACT WT ) was mutagenized to contain a methionine in the P1 residue (ACT mP1 ). ACT mP1 was then mutated to contain a lysine in the P3' residue (ACT mP1,P3' ). ACT mP1,P3' was mutagenized to contain a valine in P3 and a leucine in P4' (ACT mP3,P1,P3',P4' ). The lysine residue in P3' of ACT mP3,P1,P3',P4' was point to be a critical residue in serpina3n scanning mutagenesis, replacement of this leucine resulted in loss of GrB binding (Fig. 2D) . A mutant containing all four point mutations (ACT mP3,P1,P3′,P4′
) bound GrB less efficiently than ACT mP1 mutant (Fig. 2D) . However, removal of the P3′ lysine and replacement of this residue back to a leucine generated a mutant (ACT mP3,P1,P4′
) that could bind GrB as effectively as serpina3n.
Human ACT mP3,P1,P4' mutant prevents GrB-mediated killing of Jurkat cells
To determine the ability of human ACT mP3,P1,P4′ mutant to protect
Jurkat cells against GrB, we treated Jurkat cells with GrB/AD and measured the percentage of TUNEL-positive Jurkat cells (Fig. 3) in the presence of each mutant. For this experiment, mutants were HA tagged, then generated through IVTT and purified through affinity chromatography. We found that although ACT WT , ACT mP1 and ACT mP3,P1,P3′,P4′ were unable to prevent TUNEL staining, both serpina3n and ACT mP3,P1,P4′ significantly reduce Jurkat cell killing.
Although ACT mP1 showed strong binding to GrB (Fig. 2D) , this candidate failed to protect Jurkat cells against GrB/AD (Fig. 3) .
Human ACT mP3,P1,P4' mutant is an effective GrB inhibitor
In order to obtain sufficient quantities for analysis, the constructs were subcloned in pET3c, the leader sequence was removed, and a His-tag was added as described in the Materials and methods section. To examine the kinetic properties of this novel GrB inhibitor, serpina3n, ACT WT , ACT mP1 , ACT mP3,P1,P3′,P4′ and ACT mP3,P1,P4′ were purified by FPLC (Fig. 4A) . Hydrolysis of the GrB substrate Ac-IEPD-pNA demonstrated that in the range of GrB concentrations tested, ACT mP3,P1,P4′
was a more effective inhibitor of GrB (Fig. 4B) . At 0.5 μM ACT mP1
, there was a significant decrease in Ac-IEPD-pNA hydrolysis. This effect disappeared at lower concentrations of ACT mP1 . We concluded from these data that ACT mP1 would be an inferior drug candidate to ACT mP3,P1,P4′
. The initial interaction between a serpin and a protease results in the formation of a reversible Mechaelis complex. Following this interaction, a covalent bond is formed between the protease and the serpin resulting in an irreversible complex. The association constant (k ass ) is a kinetic factor that defines the rate at which the Michaelis complex is converted into the irreversible covalent complex. For a k ass between a serpin and a protease to be relevant, it must be in the order of 10 5 -10 7 M −1 s −1 . We measured the kass of serpina3n, ACT WT and ACT mutants (Table II resembled serpina3n in that it can also bind elastase (Fig. 5) . ACT WT did not bind GrB, GrA or elastase (data not shown).
Discussion
GrB levels are elevated in patients with various autoimmune disorders and blocking GrB activity improves symptoms in animal models. Interestingly, a naturally occurring extracellular protease inhibitor (serpin) of GrB has not been identified and GrB activity appears to be unregulated in inflammatory states. Targeting GrB provides a novel pharmaceutical method to control various inflammatory disorders. In this study, we designed a novel GrB inhibitor using the backbone of ACT, the secretory human ortholog of serpina3n (Horvath et al., 2005) . Serpins interact with their proteases through a domain called the RCL. The amino acid residues in the RCL confer serpins their specificity for the particular protease they inhibit. We took wild type ACT and replaced its RCL domain with that of the GrB inhibitor serpina3n. This mutation resulted in a chimera that bound and inhibited GrB. Scanning mutagenesis analysis on this chimera and in the native serpina3n led us to three critical mutations (ACT mP3,P1,P4′
) that converted ACT into a secretory human GrB inhibitor. ACT mP3,P1,P4′ protected Jurkat cells against GrB-induced DNA fragmentation (Fig. 3) and significantly reduced the hydrolysis of the synthetic GrB substrate Ac-IEPD-pNA in vitro (Fig. 4B) . The generally accepted range of k ass for physiological interactions between enzymes and substrates is 1 × 10 5 to 1 × 10 7 M −1 s −1 (Travis and Salvesen, 1983) . We measured the k ass of ACT mP3,P1,P4′ with GrB to be 7.65 × 10 5 M −1 s −1
, making it an effective irreversible inhibitor of GrB. This is comparable with the inhibition of chymotrypsin by ACT with a k ass of 7 × 10 5 M −1 s −1 (Rubin et al., 1990) . The reported k ass of PI9 or SERPINB9 is significantly higher with a value of 1.7 × 10 6 M −1 s −1 (Sun et al., 1996) .
Based on the k ass , PI9 appears to be a more adequate inhibitor of GrB for drug design, however, PI9 has a number of critical weaknesses. PI9 lacks a classical secretory signal peptide (Remold-O'Donnell, 1993) and as an extracellular inhibitor of GrB, PI9 would be sensitive to proteolytic inactivation and oxidation as has been shown for its close relatives SERPINB6 and SERPINB1 (Remold-O'Donnell et al., 1992; Coughlin et al., 1993) . PI9 has been detected in leukocytes like CD4+ T cells (Sharma et al., 2006) , B cells (Hagn et al., 2009) , neutrophils (Wagner et al., 2004) , basophils (Tschopp et al., 2006) , mast cells (Strik et al., 2007) , macrophages (Kim et al., 2007) , dendritic cells (Rissoan et al., 2002) and CD34+ stem cells (Berthou et al., 1995) . However, it is exclusively an intracellular protein.
Comparative molecular modeling based on the three-dimensional (3D) structure of several serine proteases allowed us to predict that GrB substrates would have a strong preference for an Asp in the P1 residue (Murphy et al., 1988) . Although our prediction was later confirmed (Thornberry et al., 1997; Harris et al., 1998) , specific inhibitors of GrB were later found to interact with GrB with P1 residues other than Asp, namely serpina3n (Met 381 ), and PI9 (Glu 340 ). The reported substrate specificity in the P4 to P2′ residues has been extensively documented for GrB (Thornberry et al., 1997; Harris et al., 1998; Ruggles et al., 2004) . These studies demonstrated that the ideal P4-P1 sequence for a GrB substrate is a tetrapeptide sequence encoded by the amino acid residues IEPD. The 3D structure of human GrB in complex with IEPD was later resolved and was used to elucidate the interactions of the enzymes' S4-S1 sites with the tetrapeptide (Rotonda et al., 2001) . The Asp specificity of GrB is due in large part to an interaction with Arg226 (Caputo et al., 1994) . However, the enzyme can also cleave synthetic substrates at Glu and Met (Poe et al., 1991) .
We found that targeted mutagenesis of the P1 residue in either serpina3n or ACT mRCL to alanine resulted in complete loss of binding to GrB (Fig. 1D) confirming the importance of the P1 residue. In addition, mutagenesis of the P1 residue to glutamic acid or aspartic acid generated mutants that recovered their ability to bind to GrB (Fig. 1D) . These results were not surprising given that reported serpin inhibitors of GrB have aspartic acid, as is the case for CrmA (Quan et al., 1995) , and glutamic acid for PI9 (Bird et al., 1998) . We noted that although the aspartic acid mutants ACT mRCL(M383D) and serpina3n mM381D were able to bind GrB (Fig. 1D) , degradation fragments were also observed, showing that these mutants were substrates for GrB. This agrees with literature showing that GrB has a strong preference for aspartic acid in the P1 site as a result of the strong salt-bridge formed between the S1 residue Arg 226 of GrB and the P1 residue on GrB substrates (Estebanez-Perpina et al., 2000) . The S3 pocket is defined by polar residues capable of forming hydrogen bonds, which explains the preference for Glu at P3. In both serpina3n and PI9, this amino acid is a hydrophobic Val. It is interesting that mutation of this Val in both of these serpins resulted in a reduction of GrB binding. Mutation of the P4′ amino acid in PI9 (Glu to Ala) resulted in a reduction of GrB binding. This was explained by the lack of a salt bridge between the Glu 344 and Lys 27 (Sun et al., 2001) . Clearly this cannot be the explanation for the result seen with serpina3n as P4′ is a hydrophobic Leu. Serpina3n (FVPM) and PI9 (VVAE) display P4-P1 residues that differ from the consensus IEPD substrate sequence. Crystal structures of GrB in complex with either serpina3n or PI9 are yet to be resolved and are necessary to understand the relevance of the dramatic change of amino acid sequences from a GrB substrate to a GrB inhibitor.
GrB is expressed extracellularly and the lack of an intrinsic extracellular inhibitor of GrB is puzzling. Extracellular GrB inhibitors like SERPINA1 (Poe et al., 1991) have been suggested but studies have shown little in vitro inhibitory activity (Tremblay et al., 2000) . High levels of extracellular GrB in disorders like multiple sclerosis, rheumatoid arthritis, chronic obstructive pulmonary disease, cystic fibrosis and sepsis, has linked GrB to the pathogenesis of these conditions. Specific animal studies show that GrB induces selective neuronal death in a multiple sclerosis mouse model (Haile et al., 2011) and inhibition of GrB with serine proteinases correlates with NK cellmediated cytolysis in rats . GrB may contribute to the pathogenesis of rheumatoid arthritis, as GrB levels are upregulated in plasma and synovial fluid of affected patients (Tak et al., 1999) , while Froelich et al. showed that GrB degrades aggrecan, an integral component of the ECM in cartilage tissue (Froelich et al., 1993) . Using a model of abdominal aortic aneurysm, Chamberlain and Ranum (2012) determined that GrB knockout mice had a reduced incidence of aneurysm rupture, while the mouse extracellular GrB inhibitor serpina3n also reduce aneurysm rupture and degrades the ECM protein decorin (Ang et al., 2011) . Extracellular GrB also cleaves and activates soluble cytokines like IL-18 (Omoto et al., 2010) and IL-1a (Afonina et al., 2011) , contributing to the progression of inflammatory disorders. Our objective for this study was to create a new protein-based GrB inhibitor that could be used to elucidate the biology of GrB and potentially be used as a drug candidate for various diseases. GrB inhibitors have been designed and used as powerful tools to study the biology of GrB. Available inhibitors can be grouped into six major classes: peptide aldehydes, peptide chloromethyl ketones, acylating agents, isocoumarins and suicide protein-based inhibitors (Kam et al., 2000) . Protein-based inhibitors like ACT mP3,P1,P4′ have several advantages to smaller synthetic inhibitors. Small synthetic inhibitors are more likely to bind to unintended sites resulting in non-specific responses and would likely have more side effects as a pharmaceutical agent. Small synthetic peptide-based drugs can be more specific but these drugs are less stable biologically and have inherent physico-chemical vulnerabilities (Banerjee and Onyuksel, 2012; Schall et al., 2012) .
In this manuscript, we described the design and characterized the enzymatic properties of a novel GrB inhibitor. ACT mP3,P1,P4′ is based on a protein (ACT) that is already found extracellularly with a minimal three-amino acid change that transforms this enzyme into a powerful GrB inhibitor. To our knowledge, this is the first report in which a set of specific mutations has been introduced into a human serpin to generate a GrB inhibitor. Purified human serpins like α-antitrypsin and antithrombin H have been clinically tested in the treatment of emphysema (Mast et al., 1990) , antitrypsin deficiency (Mordwinkin and Louie, 2007) and antithrombin deficiency during the acute phase of thermal injury (Kowal-Vern et al., 2001) . Thus, anti-proteases are effective means of reducing the expression of circulating proteases in the treatment of several disorders. Although the literature indicates that GrB could play a role in numerous conditions, there are no clinical studies using GrB inhibitors. Our novel chimera, ACT mP3,P1,P4′ , has inherent properties that make it a suitable drug candidate in the treatment of autoimmune inflammatory disorders.
